Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmun...

Full description

Bibliographic Details
Main Authors:	Ying Zhou, Elyse E. Lower, Huiping Li, Robert P. Baughman
Format:	Article
Language:	English
Published:	Elsevier 2016-01-01
Series:	Respiratory Medicine Case Reports
Subjects:	Sarcoidosis Myositis Infliximab Acthar
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213007115300526

id	doaj-c6bf877633f148daba534a488175926c
record_format	Article
spelling	doaj-c6bf877633f148daba534a488175926c2020-11-24T23:09:58ZengElsevierRespiratory Medicine Case Reports2213-00712016-01-0117C5710.1016/j.rmcr.2015.11.001Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gelYing Zhou0Elyse E. Lower1Huiping Li2Robert P. Baughman3Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USADepartment of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USADepartment of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, ChinaDepartment of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes, Eden Ave, Cincinnati, OH, 45267, USAInfliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed a myositis type reaction to infliximab characterized by diffuse muscle achiness and weakness and marked elevations in serum creatinine phosphokinase (CPK) and aldolase. Manifestations of sarcoidosis and myositis improved after Acthar treatment. This is the first report of successful treatment with Acthar in a patient with advanced sarcoidosis with an autoimmune reaction to infliximab.http://www.sciencedirect.com/science/article/pii/S2213007115300526SarcoidosisMyositisInfliximabActhar
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman
spellingShingle	Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel Respiratory Medicine Case Reports Sarcoidosis Myositis Infliximab Acthar
author_facet	Ying Zhou Elyse E. Lower Huiping Li Robert P. Baughman
author_sort	Ying Zhou
title	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
title_short	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
title_full	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
title_fullStr	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
title_full_unstemmed	Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel
title_sort	sarcoidosis patient with lupus pernio and infliximab-induced myositis: response to acthar gel
publisher	Elsevier
series	Respiratory Medicine Case Reports
issn	2213-0071
publishDate	2016-01-01
description	Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed a myositis type reaction to infliximab characterized by diffuse muscle achiness and weakness and marked elevations in serum creatinine phosphokinase (CPK) and aldolase. Manifestations of sarcoidosis and myositis improved after Acthar treatment. This is the first report of successful treatment with Acthar in a patient with advanced sarcoidosis with an autoimmune reaction to infliximab.
topic	Sarcoidosis Myositis Infliximab Acthar
url	http://www.sciencedirect.com/science/article/pii/S2213007115300526
work_keys_str_mv	AT yingzhou sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT elyseelower sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT huipingli sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel AT robertpbaughman sarcoidosispatientwithlupuspernioandinfliximabinducedmyositisresponsetoacthargel
_version_	1725608842094444544

Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel

Similar Items